RadNet, Inc.

Is RadNet, Inc. technically bullish or bearish?

As of September 26, 2025, RadNet, Inc. shows a bullish technical trend supported by daily moving averages and weekly MACD, despite mixed signals from other indicators and underperformance compared to the S&P 500 year-to-date.

As of 26 September 2025, the technical trend for RadNet, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The weekly RSI is bearish, but the monthly RSI shows no signal. Moving averages are bullish on the daily chart, supporting the overall bullish stance. Additionally, Bollinger Bands are mildly bullish weekly and bullish monthly, while the KST and OBV indicators are bullish weekly and mildly bullish monthly. <BR><BR>In terms of performance, RadNet has returned 7.57% over the past month compared to the S&P 500's 2.75%, but it has underperformed year-to-date and over the last year against the benchmark. Overall, the current technical stance is bullish, with strength indicated by the daily moving averages and the weekly MACD.

Is RadNet, Inc. overvalued or undervalued?

As of May 12, 2025, RadNet, Inc. is considered overvalued and risky due to high valuation ratios, including a P/E of 137, compared to lower ratios of peers, despite its strong historical performance.

As of 12 May 2025, the valuation grade for RadNet, Inc. has moved from fair to risky, indicating a shift towards a less favorable outlook. The company appears to be overvalued based on its high valuation ratios, including a P/E ratio of 137, an EV to EBITDA of 21.25, and a Price to Book Value of 4.90. In comparison, peers such as Encompass Health Corp. have a significantly lower P/E ratio of 20.94, while The Ensign Group, Inc. shows a P/E of 32.46, both suggesting that RadNet's valuation is not justified relative to its industry.<BR><BR>Despite RadNet's strong historical performance, with a staggering 3-year return of 282.14% compared to the S&P 500's 70.41%, the current valuation metrics indicate that the stock may be priced too high given its earnings potential. Overall, RadNet, Inc. is assessed as overvalued in the current market context.

How big is RadNet, Inc.?

As of Jun 18, RadNet, Inc. has a market capitalization of $4.24 billion, with net sales of $1.87 billion and a net profit of $3.69 million over the last four quarters. Shareholder's funds are $902.31 million, and total assets amount to $3.50 billion.

As of Jun 18, RadNet, Inc. has a market capitalization of 4,243.70 million, classifying it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 1,869.35 million, while the sum of Net Profit for the same period is 3.69 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 902.31 million and Total Assets at 3,497.16 million.

What does RadNet, Inc. do?

RadNet, Inc. is a small-cap provider of outpatient diagnostic imaging services, with recent net sales of $471 million and a net profit of -$30 million. The company has a market cap of approximately $4.24 billion and key metrics include a P/E ratio of 137.00 and a debt-to-equity ratio of 0.39.

Overview: <BR>RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 471 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4,243.70 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 137.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.39 <BR>Return on Equity: 3.57% <BR>Price to Book: 4.72<BR><BR>Contact Details: <BR>Address: 1510 Cotner Ave, LOS ANGELES CA: 90025-3303 <BR>Tel: 1 310 4787808 <BR>Website: https://www.radnet.com/

Should I buy, sell or hold RadNet, Inc.?

Who are in the management team of RadNet, Inc.?

As of March 2022, RadNet, Inc.'s management team includes Dr. Howard Berger (Chairman, CEO), Ms. Ruth Wilson (SVP of Human Resources), Dr. John Crues (VP, Medical Director), and several independent directors, including Mr. David Swartz, Mr. Marvin Cadwell, Mr. Lawrence Levitt, and Dr. Michael Sherman. This team is responsible for the company's strategic direction and operations.

As of March 2022, the management team of RadNet, Inc. includes the following individuals:<BR><BR>- Dr. Howard Berger: Chairman of the Board, President, Chief Executive Officer, and Director<BR>- Ms. Ruth Wilson: Senior Vice President of Human Resources and Director<BR>- Dr. John Crues: Vice President, Medical Director, Director, and Corporate Secretary<BR>- Mr. David Swartz: Lead Independent Director<BR>- Mr. Marvin Cadwell: Independent Director<BR>- Mr. Lawrence Levitt: Independent Director<BR>- Dr. Michael Sherman: Independent Director<BR><BR>This team oversees the strategic direction and operations of the company.